On October 13, 2020 Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, reported that it will participate virtually in two upcoming conferences in October (Press release, Eureka Therapeutics, OCT 13, 2020, View Source [SID1234568418]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TCR-based Therapies Summit
Title: ARTEMIS Antibody TCR T Cell Therapies for Solid Tumors
Speaker: Cheng Liu, Ph.D., President and CEO
Date: Tuesday, October 27, 2020
Time: 9:00 a.m. EST
Cell & Gene Therapy Bioprocessing & Commercialization
Title: Optimizing Viral Vector Production
Speaker: Nicole Nunez, Ph.D., Process Development Scientist
Date: Thursday, October 22, 2020
Time: 8:00 a.m. EST